Impel Pharmaceuticals, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals: Major
  • ISIN: US45258K1097
USD
0.01
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

5.48 k

Shareholding (Dec 2023)

FII

0.20%

Held by 14 FIIs

DII

29.03%

Held by 7 DIIs

Promoter

65.87%

How big is Impel Pharmaceuticals, Inc.?

22-Jun-2025

As of Apr 05, Impel Pharmaceuticals, Inc. has a market capitalization of 0.36 million and reported net sales of 20.98 million, with a net profit of -74.28 million over the latest four quarters.

As of Apr 05, Impel Pharmaceuticals, Inc. has a market capitalization of 0.36 million, categorizing it as a Micro Cap company.<BR><BR>As of Apr 05, the company reported net sales of 20.98 million for the latest four quarters. However, it also recorded a net profit of -74.28 million during the same period.<BR><BR>As of Dec 22, the company's balance sheet shows shareholder's funds of -44.16 million and total assets amounting to 88.55 million.

Read More

What does Impel Pharmaceuticals, Inc. do?

22-Jun-2025

Impel Pharmaceuticals, Inc. is a micro-cap pharmaceutical company with quarterly net sales of $5 million and a net loss of $14 million as of September 2023. It has a market cap of $0.36 million and does not pay dividends.

Overview:<BR>Impel Pharmaceuticals, Inc. operates within the pharmaceuticals industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Net Sales: 5 Million (Quarterly Results - Sep 2023)<BR>- Net Profit: -14 Million (Quarterly Results - Sep 2023)<BR>- Market cap: USD 0.36 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -1.17<BR>- Return on Equity: 68.81%<BR>- Price to Book: -0.00<BR><BR>Contact Details:<BR>Details: No Company Details Available<BR>Registrar Address: Not available.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals: Major

stock-summary
Market cap

USD 0 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.17

stock-summary
Return on Equity

68.81%

stock-summary
Price to Book

-0.00

Revenue and Profits:
Net Sales:
5 Million
(Quarterly Results - Sep 2023)
Net Profit:
-14 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-85.0%
0%
-85.0%
6 Months
-96.45%
0%
-96.45%
1 Year
-98.82%
0%
-98.82%
2 Years
-99.78%
0%
-99.78%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Impel Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
17.68%
EBIT Growth (5y)
-290.15%
EBIT to Interest (avg)
-6.40
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.17
Sales to Capital Employed (avg)
0.34
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
77.07%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.00
EV to EBIT
-1.54
EV to EBITDA
-1.59
EV to Capital Employed
6.80
EV to Sales
5.15
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-440.47%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 13 Schemes (4.9%)

Foreign Institutions

Held by 14 Foreign Institutions (0.2%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'23 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2023 is -24.24% vs 50.00% in Jun 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2023 is -86.49% vs 75.42% in Jun 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'23",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5.00",
          "val2": "6.60",
          "chgp": "-24.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.20",
          "val2": "-15.70",
          "chgp": "22.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.70",
          "val2": "3.00",
          "chgp": "23.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.80",
          "val2": "-7.40",
          "chgp": "-86.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,550.50%",
          "val2": "-2,445.90%",
          "chgp": "-10.46%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 1,714.29% vs 0.00% in Dec 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is -38.95% vs -67.03% in Dec 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "12.70",
          "val2": "0.70",
          "chgp": "1,714.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-82.00",
          "val2": "-70.40",
          "chgp": "-16.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "13.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-11.30",
          "val2": "-3.00",
          "chgp": "-276.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-106.30",
          "val2": "-76.50",
          "chgp": "-38.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-6,574.80%",
          "val2": "-107,015.00%",
          "chgp": "10,044.02%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'23 - QoQstock-summary
Sep'23
Jun'23
Change(%)
Net Sales
5.00
6.60
-24.24%
Operating Profit (PBDIT) excl Other Income
-12.20
-15.70
22.29%
Interest
3.70
3.00
23.33%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-13.80
-7.40
-86.49%
Operating Profit Margin (Excl OI)
-2,550.50%
-2,445.90%
-10.46%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2023 is -24.24% vs 50.00% in Jun 2023

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2023 is -86.49% vs 75.42% in Jun 2023

Annual Results Snapshot (Consolidated) - Dec'22stock-summary
Dec'22
Dec'21
Change(%)
Net Sales
12.70
0.70
1,714.29%
Operating Profit (PBDIT) excl Other Income
-82.00
-70.40
-16.48%
Interest
13.80
0.00
Exceptional Items
-11.30
-3.00
-276.67%
Consolidate Net Profit
-106.30
-76.50
-38.95%
Operating Profit Margin (Excl OI)
-6,574.80%
-107,015.00%
10,044.02%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2022 is 1,714.29% vs 0.00% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is -38.95% vs -67.03% in Dec 2021

stock-summaryCompany CV
About Impel Pharmaceuticals, Inc. stock-summary
stock-summary
Impel Pharmaceuticals, Inc.
Pharmaceuticals: Major
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available